NanHua Bio-medicine Co., Ltd Logo

NanHua Bio-medicine Co., Ltd

000504.SZ

(0.5)
Stock Price

9,15 CNY

-4.78% ROA

-14.26% ROE

-109.5x PER

Market Cap.

3.023.010.680,00 CNY

5.72% DER

0% Yield

-22.49% NPM

NanHua Bio-medicine Co., Ltd Stock Analysis

NanHua Bio-medicine Co., Ltd Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

NanHua Bio-medicine Co., Ltd Fundamental Stock Analysis
# Analysis Rating
1 Revenue Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

2 Net Profit Growth

The net profit of this company has shown steady growth over the past three years, highlighting its positive financial trajectory and making it an appealing choice for potential investors.

3 ROE

The stock's ROE indicates a negative return (-313.93%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-6.57%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 PBV

The stock's high Price-to-Book Value (P/BV) ratio (259.95x) suggests it's overvalued, potentially making it an expensive investment.

6 DER

The company has a high debt to equity ratio (376%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

NanHua Bio-medicine Co., Ltd Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

NanHua Bio-medicine Co., Ltd Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

NanHua Bio-medicine Co., Ltd Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

NanHua Bio-medicine Co., Ltd Revenue
Year Revenue Growth
1992 176.627.235
1993 319.915.314 44.79%
1994 138.928.785 -130.27%
1995 48.346.863 -187.36%
1996 -98.390.829 149.14%
1997 169.941.246 157.9%
1998 -52.417.840 424.2%
1999 -30.064.410 -74.35%
2000 21.575.481 239.35%
2001 175.217.272 87.69%
2002 249.512.873 29.78%
2003 255.944.522 2.51%
2004 273.761.205 6.51%
2005 222.488.100 -23.05%
2006 227.939.136 2.39%
2007 319.085.934 28.56%
2008 197.455.710 -61.6%
2009 178.309.954 -10.74%
2010 151.990.369 -17.32%
2011 90.893.027 -67.22%
2012 76.816.619 -18.32%
2013 26.280.915 -192.29%
2014 18.372.828 -43.04%
2015 13.374.222 -37.37%
2016 67.251.431 80.11%
2017 67.392.990 0.21%
2018 95.381.715 29.34%
2019 134.160.531 28.9%
2020 175.564.990 23.58%
2021 156.618.305 -12.1%
2022 200.345.457 21.83%
2023 137.304.602 -45.91%
2023 136.790.924 -0.38%
2024 121.403.752 -12.67%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

NanHua Bio-medicine Co., Ltd Research and Development Expenses
Year Research and Development Expenses Growth
1992 0
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 397.056 100%
2017 2.728.933 85.45%
2018 16.069.891 83.02%
2019 15.515.677 -3.57%
2020 4.976.335 -211.79%
2021 8.543.248 41.75%
2022 9.985.226 14.44%
2023 10.314.336 3.19%
2023 12.567.051 17.93%
2024 7.526.416 -66.97%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

NanHua Bio-medicine Co., Ltd General and Administrative Expenses
Year General and Administrative Expenses Growth
1992 5.381.412
1993 10.482.137 48.66%
1994 16.257.246 35.52%
1995 9.443.642 -72.15%
1996 16.769.308 43.68%
1997 13.896.594 -20.67%
1998 19.739.066 29.6%
1999 17.574.460 -12.32%
2000 3.369.447 -421.58%
2001 35.199.704 90.43%
2002 45.237.556 22.19%
2003 44.457.320 -1.76%
2004 42.455.414 -4.72%
2005 39.675.959 -7.01%
2006 35.355.062 -12.22%
2007 32.638.618 -8.32%
2008 32.103.424 -1.67%
2009 33.954.575 5.45%
2010 23.478.292 -44.62%
2011 9.520.607 -146.6%
2012 6.283.893 -51.51%
2013 6.845.247 8.2%
2014 8.464.652 19.13%
2015 7.081.192 -19.54%
2016 13.499.771 47.55%
2017 22.447.254 39.86%
2018 13.447.812 -66.92%
2019 13.839.924 2.83%
2020 10.427.408 -32.73%
2021 13.880.853 24.88%
2022 15.326.502 9.43%
2023 122.278.408 87.47%
2023 14.477.287 -744.62%
2024 -20.028.742 172.28%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

NanHua Bio-medicine Co., Ltd EBITDA
Year EBITDA Growth
1992 70.468.366
1993 161.964.247 56.49%
1994 78.177.398 -107.18%
1995 10.542.760 -641.53%
1996 -93.212.422 111.31%
1997 9.554.818 1075.55%
1998 48.274.461 80.21%
1999 -86.839.103 155.59%
2000 -41.496.645 -109.27%
2001 30.314.768 236.89%
2002 41.534.763 27.01%
2003 50.274.078 17.38%
2004 43.535.755 -15.48%
2005 16.831.891 -158.65%
2006 16.732.922 -0.59%
2007 26.497.384 36.85%
2008 -15.656.351 269.24%
2009 -19.117.245 18.1%
2010 37.390.293 151.13%
2011 -7.101.604 626.5%
2012 23.606.396 130.08%
2013 31.056.305 23.99%
2014 -12.997.407 338.94%
2015 -10.950.699 -18.69%
2016 41.343.905 126.49%
2017 -23.424.485 276.5%
2018 -9.050.768 -158.81%
2019 40.846.566 122.16%
2020 28.601.965 -42.81%
2021 11.277.872 -153.61%
2022 23.285.552 51.57%
2023 129.130 -17932.78%
2023 1.172.974 88.99%
2024 -11.093.881 110.57%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

NanHua Bio-medicine Co., Ltd Gross Profit
Year Gross Profit Growth
1992 85.967.559
1993 201.363.780 57.31%
1994 103.383.252 -94.77%
1995 23.164.574 -346.3%
1996 -80.092.530 128.92%
1997 34.161.903 334.45%
1998 -39.479.978 186.53%
1999 -51.011.534 22.61%
2000 78.116 65402.29%
2001 87.625.156 99.91%
2002 110.433.671 20.65%
2003 114.650.967 3.68%
2004 111.634.876 -2.7%
2005 78.301.439 -42.57%
2006 69.700.258 -12.34%
2007 61.382.096 -13.55%
2008 27.165.085 -125.96%
2009 20.087.849 -35.23%
2010 34.394.247 41.6%
2011 19.186.317 -79.26%
2012 28.939.756 33.7%
2013 -1.120.786 2682.09%
2014 4.925.131 122.76%
2015 1.443.104 -241.29%
2016 21.667.640 93.34%
2017 17.805.237 -21.69%
2018 62.771.795 71.63%
2019 84.478.288 25.69%
2020 97.481.656 13.34%
2021 110.934.885 12.13%
2022 129.807.372 14.54%
2023 94.686.295 -37.09%
2023 93.104.470 -1.7%
2024 79.748.528 -16.75%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

NanHua Bio-medicine Co., Ltd Net Profit
Year Net Profit Growth
1992 62.955.707
1993 128.795.162 51.12%
1994 56.345.529 -128.58%
1995 -9.111.002 718.43%
1996 -96.963.133 90.6%
1997 10.378.455 1034.27%
1998 -189.636.636 105.47%
1999 -56.618.393 -234.94%
2000 28.261.411 300.34%
2001 5.093.332 -454.87%
2002 29.036.273 82.46%
2003 31.854.064 8.85%
2004 29.800.063 -6.89%
2005 2.054.002 -1350.83%
2006 2.227.495 7.79%
2007 3.668.877 39.29%
2008 -170.063.904 102.16%
2009 -134.656.727 -26.29%
2010 6.461.335 2184.04%
2011 -29.903.147 121.61%
2012 -149.231.238 79.96%
2013 13.801.492 1181.27%
2014 -26.151.229 152.78%
2015 -21.217.954 -23.25%
2016 21.756.098 197.53%
2017 -37.119.370 158.61%
2018 -35.188.300 -5.49%
2019 18.806.368 287.11%
2020 14.635.465 -28.5%
2021 -33.101.048 144.21%
2022 -29.761.420 -11.22%
2023 37.839.493 178.65%
2023 -28.172.626 234.31%
2024 -22.488.707 -25.27%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

NanHua Bio-medicine Co., Ltd Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1992 0
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 -1 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 -1 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

NanHua Bio-medicine Co., Ltd Free Cashflow
Year Free Cashflow Growth
1998 3.201.686
1999 -2.640.067 221.27%
2000 -3.489.285 24.34%
2001 32.190.085 110.84%
2002 15.582.083 -106.58%
2003 48.369.534 67.79%
2004 10.547.141 -358.6%
2005 9.764.851 -8.01%
2006 -829.062 1277.82%
2007 8.534.912 109.71%
2008 -20.880.659 140.87%
2009 59.910.698 134.85%
2010 -65.799.275 191.05%
2011 -3.344.594 -1867.33%
2012 -4.364.334 23.37%
2013 -35.435.899 87.68%
2014 -32.877.589 -7.78%
2015 -29.639.899 -10.92%
2016 -18.861.449 -57.15%
2017 -48.433.951 61.06%
2018 -24.485.802 -97.8%
2019 11.948.070 304.94%
2020 -211.688.139 105.64%
2021 75.136.422 381.74%
2022 149.438.444 49.72%
2023 30.358.412 -392.25%
2023 -6.108.006 597.03%
2024 5.001.535 222.12%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

NanHua Bio-medicine Co., Ltd Operating Cashflow
Year Operating Cashflow Growth
1998 3.315.580
1999 -1.933.018 271.52%
2000 -3.362.080 42.51%
2001 34.223.172 109.82%
2002 15.834.050 -116.14%
2003 55.746.915 71.6%
2004 13.306.408 -318.95%
2005 11.397.589 -16.75%
2006 717.615 -1488.26%
2007 9.215.819 92.21%
2008 -18.590.015 149.57%
2009 60.277.698 130.84%
2010 -63.948.511 194.26%
2011 -3.123.114 -1947.59%
2012 -4.275.759 26.96%
2013 -11.742.069 63.59%
2014 -32.601.255 63.98%
2015 -17.169.761 -89.88%
2016 -14.604.165 -17.57%
2017 -47.403.365 69.19%
2018 -15.187.480 -212.12%
2019 14.522.362 204.58%
2020 -207.220.872 107.01%
2021 107.098.005 293.49%
2022 166.381.243 35.63%
2023 36.276.713 -358.64%
2023 0 0%
2024 5.119.946 100%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

NanHua Bio-medicine Co., Ltd Capital Expenditure
Year Capital Expenditure Growth
1998 113.894
1999 707.049 83.89%
2000 127.205 -455.83%
2001 2.033.087 93.74%
2002 251.967 -706.89%
2003 7.377.380 96.58%
2004 2.759.267 -167.37%
2005 1.632.738 -69%
2006 1.546.677 -5.56%
2007 680.907 -127.15%
2008 2.290.644 70.27%
2009 367.000 -524.15%
2010 1.850.764 80.17%
2011 221.480 -735.63%
2012 88.575 -150.05%
2013 23.693.829 99.63%
2014 276.334 -8474.34%
2015 12.470.138 97.78%
2016 4.257.284 -192.91%
2017 1.030.586 -313.09%
2018 9.298.322 88.92%
2019 2.574.292 -261.2%
2020 4.467.267 42.37%
2021 31.961.582 86.02%
2022 16.942.799 -88.64%
2023 5.918.300 -186.28%
2023 6.108.006 3.11%
2024 118.411 -5058.35%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

NanHua Bio-medicine Co., Ltd Equity
Year Equity Growth
1989 3.770.000
1990 59.263.652 93.64%
1991 110.536.606 46.39%
1992 174.341.818 36.6%
1993 553.600.889 68.51%
1994 605.956.712 8.64%
1995 624.177.047 2.92%
1996 541.094.338 -15.35%
1997 551.137.364 1.82%
1998 352.685.406 -56.27%
1999 173.522.858 -103.25%
2000 385.749.177 55.02%
2001 322.289.555 -19.69%
2002 387.298.291 16.79%
2003 423.500.101 8.55%
2004 443.855.141 4.59%
2005 445.857.982 0.45%
2006 443.775.959 -0.47%
2007 449.000.298 1.16%
2008 278.159.747 -61.42%
2009 144.297.948 -92.77%
2010 161.134.438 10.45%
2011 130.379.900 -23.59%
2012 -20.802.968 726.74%
2013 3.570.588 682.62%
2014 7.027.165 49.19%
2015 -14.505.165 148.45%
2016 79.757.178 118.19%
2017 128.432.078 37.9%
2018 107.751.017 -19.19%
2019 114.456.024 5.86%
2020 134.481.489 14.89%
2021 110.319.278 -21.9%
2022 79.884.199 -38.1%
2023 84.593.436 5.57%
2023 304.673.867 72.23%
2024 292.794.695 -4.06%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

NanHua Bio-medicine Co., Ltd Assets
Year Assets Growth
1989 19.006.768
1990 83.178.419 77.15%
1991 223.405.101 62.77%
1992 455.240.845 50.93%
1993 782.336.932 41.81%
1994 831.098.636 5.87%
1995 861.025.048 3.48%
1996 766.943.131 -12.27%
1997 743.862.481 -3.1%
1998 631.047.539 -17.88%
1999 479.487.219 -31.61%
2000 597.048.948 19.69%
2001 600.982.752 0.65%
2002 620.071.933 3.08%
2003 595.751.055 -4.08%
2004 603.884.799 1.35%
2005 648.022.899 6.81%
2006 637.477.871 -1.65%
2007 681.310.775 6.43%
2008 536.522.987 -26.99%
2009 412.243.437 -30.15%
2010 286.824.436 -43.73%
2011 276.472.625 -3.74%
2012 76.059.874 -263.49%
2013 125.894.719 39.58%
2014 106.632.343 -18.06%
2015 122.757.385 13.14%
2016 301.187.324 59.24%
2017 404.775.978 25.59%
2018 342.705.746 -18.11%
2019 268.330.903 -27.72%
2020 556.140.141 51.75%
2021 659.245.600 15.64%
2022 553.064.727 -19.2%
2023 542.187.740 -2.01%
2023 771.382.516 29.71%
2024 579.563.143 -33.1%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

NanHua Bio-medicine Co., Ltd Liabilities
Year Liabilities Growth
1989 15.236.768
1990 23.914.766 36.29%
1991 112.868.494 78.81%
1992 280.899.027 59.82%
1993 228.736.043 -22.8%
1994 225.141.923 -1.6%
1995 236.848.001 4.94%
1996 225.848.792 -4.87%
1997 192.725.116 -17.19%
1998 278.362.132 30.76%
1999 305.964.360 9.02%
2000 211.299.770 -44.8%
2001 278.693.197 24.18%
2002 232.773.642 -19.73%
2003 172.250.953 -35.14%
2004 160.029.657 -7.64%
2005 202.164.917 20.84%
2006 193.701.912 -4.37%
2007 232.310.476 16.62%
2008 258.363.240 10.08%
2009 267.945.488 3.58%
2010 125.689.997 -113.18%
2011 146.092.724 13.97%
2012 96.862.841 -50.82%
2013 122.324.130 20.81%
2014 99.605.176 -22.81%
2015 137.262.550 27.43%
2016 221.430.144 38.01%
2017 276.343.899 19.87%
2018 234.954.728 -17.62%
2019 153.874.879 -52.69%
2020 421.658.651 63.51%
2021 548.926.321 23.18%
2022 473.180.527 -16.01%
2023 457.594.304 -3.41%
2023 466.708.647 1.95%
2024 286.768.447 -62.75%

NanHua Bio-medicine Co., Ltd Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.37
Net Income per Share
-0.08
Price to Earning Ratio
-109.5x
Price To Sales Ratio
24.64x
POCF Ratio
98.18
PFCF Ratio
128.72
Price to Book Ratio
12.16
EV to Sales
23.09
EV Over EBITDA
-236.14
EV to Operating CashFlow
92.05
EV to FreeCashFlow
120.62
Earnings Yield
-0.01
FreeCashFlow Yield
0.01
Market Cap
3,02 Bil.
Enterprise Value
2,83 Bil.
Graham Number
1.19
Graham NetNet
0.41

Income Statement Metrics

Net Income per Share
-0.08
Income Quality
-1.12
ROE
-0.14
Return On Assets
-0.05
Return On Capital Employed
-0.17
Net Income per EBT
0.55
EBT Per Ebit
1
Ebit per Revenue
-0.41
Effective Tax Rate
-0.04

Margins

Sales, General, & Administrative to Revenue
0.11
Research & Developement to Revenue
0.1
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.68
Operating Profit Margin
-0.41
Pretax Profit Margin
-0.41
Net Profit Margin
-0.22

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.42
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.09
Free CashFlow per Share
0.07
Capex to Operating CashFlow
0.24
Capex to Revenue
0.06
Capex to Depreciation
0.66
Return on Invested Capital
-0.2
Return on Tangible Assets
-0.05
Days Sales Outstanding
413.24
Days Payables Outstanding
741.29
Days of Inventory on Hand
170.02
Receivables Turnover
0.88
Payables Turnover
0.49
Inventory Turnover
2.15
Capex per Share
0.02

Balance Sheet

Cash per Share
0,93
Book Value per Share
0,89
Tangible Book Value per Share
0.88
Shareholders Equity per Share
0.75
Interest Debt per Share
0.06
Debt to Equity
0.06
Debt to Assets
0.02
Net Debt to EBITDA
15.87
Current Ratio
1.72
Tangible Asset Value
0,29 Bil.
Net Current Asset Value
0,19 Bil.
Invested Capital
225866416
Working Capital
0,20 Bil.
Intangibles to Total Assets
0
Average Receivables
0,14 Bil.
Average Payables
0,08 Bil.
Average Inventory
16328390
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

NanHua Bio-medicine Co., Ltd Dividends
Year Dividends Growth
1993 0
2004 0 0%

NanHua Bio-medicine Co., Ltd Profile

About NanHua Bio-medicine Co., Ltd

NanHua Bio-medicine Co., Ltd. provides stem and immune cell storage, noninvasive genetic testing, and biological research and technical services. The company is based in Changsha, China.

CEO
Mr. Changqiao You
Employee
512
Address
Caixin Building
Changsha, 410205

NanHua Bio-medicine Co., Ltd Executives & BODs

NanHua Bio-medicine Co., Ltd Executives & BODs
# Name Age
1 Mr. Changqiao You
GM & Director
70
2 Mr. Liang Su
Secretary of the Board
70
3 Mr. Yong Chen
Deputy General Manager
70
4 Mr. Ailong Liu
Deputy General Manager
70
5 Mr. Pengbin Lin
Deputy GM & Chief Financial Officer
70

NanHua Bio-medicine Co., Ltd Competitors